Steve. you, Thank
portfolio the have been of understanding of and growing resulted system melonocortin the know, melanocortin indications. therapeutics. for the developing on variety has our of you These biology in a with selective efforts melanocortin-based a As focus chemistry of agonists goal research
all mid-XXXX pending clinical and clinical resources, programs X have programs coming planning X agonist initiate highly are melanocortin We productive in research our by from based activities. enrollment to new on
We us MELODY-X highlight there dry approved from and eye symptom efficacy therapies with that that earlier quarter. differentiate ocular a that reaching results symptom excited. and the Now weeks, [indiscernible] and any I'd development statistical ocular both artificial PL-XXXX. and endpoint was product point tier. symptoms PL-XXXX think or positive has to see for tolerability of our secondary evaluated. current similar we for program, there's I primary to in the PL-XXXX don't and like disease earliest We out signs of the significance very safety, endpoints that key excellent essentially disease at rapid reported see we dry the eye XX of tolerability which have pain X III onset some time dry of of findings X potential in the partners Phase
Very of endpoints multiple symptom weeks the treatment. importantly, we improvement see continue of to over full XX
believe to as see the longer reached program, and more even Phase efficacy not yet, that maximal in efficacy III we upcoming treat have for we continue We we'll PL-XXXX.
to We we have the for and upcoming anticipate Type program support study which remaining in studies to half discuss the new FDA the a second we second of preparing the 'XX currently submission of application are C begin enrollment clinical the will half that remaining meeting do. calendar the with to in ] drug now [
disease. and significantly a with top data patients inflammatory assessment release and it Resolving development evaluating study Our oral colitis Phase inflammation PL-XXXX demonstrating treatment kidney with that disease colons also for of also data melanocortin-X studies safety on to or other rather agonist cites and a as on selective of Phase our preclinical treating provides an II receptor of track for toward in than in ulcerative efficacy and to release disease interim is Supporting differentiating mid-XXXX. diabetic possibility II line in patients resolve evaluating study XXXX healthy with is bowel Breakout improve inflammation. melanocortin oral track types well. coupled open-label mid-XXXX agonist state causes and PL-XXXX blocking
options. minute chemistry take These therapeutic new are melanocortin clinical this we need X expertise receptor new on large to both leverage have I'd X in programs strong they X planning address that validation highlight starting [ year. extensive in a and to a clinical of like our biology programs agonist, and ] of markets the
in enroll currently using milligrams bremelanotide, will increased clinical the are that X.X these [indiscernible], and in is of at is to that The tusepatide. Phase ] endpoint secondary primary evaluate bremelanotide II trusted first safety effect up reducing to of a appetite a using maintenance the efficacy [ coadministration weekly. endpoint loss is The stopped patients of study evaluate patients has XX weight designed obesity which of to
initial in obesity key patients. for application general, beyond VC drug loss hosted and are in and in the The GLPs, we our FDA, protocol study this this maintenance. by the leader weight for the enrolling multiple reviewed study recently treating titled receptor agonist novel program to we a opinion melanocortin-X and begin roles has clear Supporting
multiple from as for of [ Richards in treatments need receptor melanocortin Oklahoma, the maintenance. discussed was he in melanocortin The uses continued speaker obesity for agonist, is receptor X of ] University Dr. coadministration and ] and treating loss Jesse which epatide [ obesity agonist patients, the weight novel the obese
obesity loss and loss needed. will be targeting the of and multiple Drug our affect are that on and of weight treatment actions weight now the maintenance. We part different treatment of is loss link drugs recording rapidly. believe You event growing We believe strongly that an obesity website. melanocortin future the of find weight maintenance importantly, can important established drugs with mechanisms receptor system
melanocortin-based be extensive and loss maintenance. development X obesity previously we experience leader therapeutics studies agonist for of for in include loss and and clinical of a positioned treating completed in and are Our weight development the the to weight published, melanocortin design well
We are [indiscernible] a a of evaluating PD-X Phase PD-X planning study bremelanotide inhibitor also treating coadministration a at II the failed clinical for with monotherapy. patients inhibitor
direct commercial a in co-formulation efforts which [indiscernible]. is study fail have development [indiscernible] Approximately are for or by underserved and a program agri, options men ] market. implants. will of represent retile an a patients support inhibitor injections phenol the penal a are or only product, with for an combination highly like clinical XX% these [ This inadequate and of response things to and The the phosphodiesterase-X such PDX invasive with failure treatment our treatments, of inhibitor, these extension large bremelanotide dysfunction sexual as
clinical rectal successful for PDX as bremelanotide conducted and product. well an the ramp synergistic with And treatment studies feel positioned combining previously of co showing development formula the have for efficient dysfunction. effects a of inhibitor a We
highlights III disease. for for efficacy reported positive XXXX PL-XXXX rapid highly multiple Key clinical onset And a study. and quarter relief the are as ocular disease with the of Phase as and dry disease results year eye treatment from differentiated DRI for fiscal emerging eye third PL-XXXX tolerability, dry MELODY-X is broad follows: of We excellent symptoms
We are II XXXX. that planning with clinical Phase have on readouts initiating studies data X in [indiscernible]
Conference to from Call. advance Phase I Steve to multiple you calendar for with milestones initiation would data Quarter the enable the studies clinical remaining Finally, Third PL-XXXX Year of programs and programs thank Fiscal XXXX end. listening year the by and [indiscernible] Palatin our to III like continue clinical
You find on information thank Vyleesi And the website, questions. now can additional information you our call can to open our find like www.palatin.com. and additional science vyleesi.com to at programs on and on you website. We'd clinical
